Our study clarifies the impact of IBD medications on the development of hyperlipidemia, and the decreased risk of hyperlipidemia in patients receiving treatment may be due to drug-induced downregulation of lipogenic genes, especially the master lipogenic transcription factors, SREBP-1c and LXRα. The gene discussed is SREBF1; the disease is hyperlipidemia.